Chinese General Practice ›› 2024, Vol. 27 ›› Issue (06): 733-738.DOI: 10.12114/j.issn.1007-9572.2023.0118
Special Issue: 肺癌最新文章合集; 中医最新文章合集
• Original Research • Previous Articles Next Articles
Received:
2023-01-10
Revised:
2023-05-10
Published:
2024-02-20
Online:
2023-11-21
Contact:
SUN Jingyun
通讯作者:
孙静云
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0118
组别 | 例数 | 性别 | 年龄 | 肿瘤类型 | 肿瘤分期 | 化疗方案 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | <60岁 | ≥60岁 | 腺癌 | 鳞癌 | 其他 | Ⅱ~Ⅲ期 | Ⅳ期 | 顺铂+紫杉醇(TP) | 顺铂+培美曲塞(AP) | 顺铂+吉西他滨(GP) | ||
对照组 | 47 | 36(76.6) | 11(23.4) | 17(36.2) | 30(63.8) | 27(57.5) | 16(34.0) | 4(8.5) | 12(25.5) | 35(74.5) | 14(29.8) | 23(48.9) | 10(21.3) |
揿针组 | 48 | 34(70.8) | 14(29.2) | 14(29.2) | 34(70.8) | 25(52.1) | 21(43.8) | 2(4.1) | 18(37.5) | 30(62.5) | 13(27.1) | 21(43.8) | 14(29.1) |
择时组 | 47 | 37(78.7) | 10(21.3) | 22(46.8) | 25(53.2) | 24(51.1) | 18(38.3) | 5(10.6) | 15(31.9) | 32(68.1) | 16(34.0) | 18(38.3) | 13(27.7) |
χ2值 | 0.854 | 3.199 | 2.173 | 1.573 | 1.631 | ||||||||
P值 | 0.652 | 0.202 | 0.711 | 0.455 | 0.803 |
Table 1 Comparison of baseline information among the three groups
组别 | 例数 | 性别 | 年龄 | 肿瘤类型 | 肿瘤分期 | 化疗方案 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | <60岁 | ≥60岁 | 腺癌 | 鳞癌 | 其他 | Ⅱ~Ⅲ期 | Ⅳ期 | 顺铂+紫杉醇(TP) | 顺铂+培美曲塞(AP) | 顺铂+吉西他滨(GP) | ||
对照组 | 47 | 36(76.6) | 11(23.4) | 17(36.2) | 30(63.8) | 27(57.5) | 16(34.0) | 4(8.5) | 12(25.5) | 35(74.5) | 14(29.8) | 23(48.9) | 10(21.3) |
揿针组 | 48 | 34(70.8) | 14(29.2) | 14(29.2) | 34(70.8) | 25(52.1) | 21(43.8) | 2(4.1) | 18(37.5) | 30(62.5) | 13(27.1) | 21(43.8) | 14(29.1) |
择时组 | 47 | 37(78.7) | 10(21.3) | 22(46.8) | 25(53.2) | 24(51.1) | 18(38.3) | 5(10.6) | 15(31.9) | 32(68.1) | 16(34.0) | 18(38.3) | 13(27.7) |
χ2值 | 0.854 | 3.199 | 2.173 | 1.573 | 1.631 | ||||||||
P值 | 0.652 | 0.202 | 0.711 | 0.455 | 0.803 |
组别 | 例数 | 化疗前1 d | 化疗第3天 | 化疗第7天 | 化疗第14天 | 化疗第21天 |
---|---|---|---|---|---|---|
对照组 | 47 | 6.48±1.11 | 5.35±1.42 | 4.52±1.02 | 4.03±1.35 | 5.76±1.38 |
揿针组 | 48 | 6.71±1.22 | 5.71±1.52 | 5.14±1.16a | 4.66±1.43a | 6.05±1.07 |
择时组 | 47 | 6.88±1.09 | 5.81±1.60 | 5.73±1.65ab | 5.27±1.65ab | 6.16±1.05 |
F值 | F组间=14.988,F时间=52.138,F交互=1.393 | |||||
P值 | P组间<0.010,P时间<0.010,P交互=0.203 |
Table 2 Comparison of white blood cell counts before and after chemotherapy in the three groups
组别 | 例数 | 化疗前1 d | 化疗第3天 | 化疗第7天 | 化疗第14天 | 化疗第21天 |
---|---|---|---|---|---|---|
对照组 | 47 | 6.48±1.11 | 5.35±1.42 | 4.52±1.02 | 4.03±1.35 | 5.76±1.38 |
揿针组 | 48 | 6.71±1.22 | 5.71±1.52 | 5.14±1.16a | 4.66±1.43a | 6.05±1.07 |
择时组 | 47 | 6.88±1.09 | 5.81±1.60 | 5.73±1.65ab | 5.27±1.65ab | 6.16±1.05 |
F值 | F组间=14.988,F时间=52.138,F交互=1.393 | |||||
P值 | P组间<0.010,P时间<0.010,P交互=0.203 |
组别 | 例数 | 化疗前1d | 化疗第3天 | 化疗第7天 | 化疗第14天 | 化疗第21天 |
---|---|---|---|---|---|---|
对照组 | 47 | 4.26±0.93 | 3.53±0.84 | 2.46±0.70 | 2.28±0.85 | 3.67±1.02 |
揿针组 | 48 | 4.44±0.97 | 3.62±0.85 | 2.93±0.74a | 2.72±1.04a | 3.97±0.91 |
择时组 | 47 | 4.22±0.92 | 3.64±1.14 | 3.43±1.35ab | 3.16±1.03ab | 3.98±0.94 |
F值 | F组间=11.352,F时间=68.960,F交互=2.928 | |||||
P值 | P组间<0.010,P时间<0.010,P交互<0.010 |
Table 3 Comparison of neutrophils counts before and after chemotherapy among the three groups
组别 | 例数 | 化疗前1d | 化疗第3天 | 化疗第7天 | 化疗第14天 | 化疗第21天 |
---|---|---|---|---|---|---|
对照组 | 47 | 4.26±0.93 | 3.53±0.84 | 2.46±0.70 | 2.28±0.85 | 3.67±1.02 |
揿针组 | 48 | 4.44±0.97 | 3.62±0.85 | 2.93±0.74a | 2.72±1.04a | 3.97±0.91 |
择时组 | 47 | 4.22±0.92 | 3.64±1.14 | 3.43±1.35ab | 3.16±1.03ab | 3.98±0.94 |
F值 | F组间=11.352,F时间=68.960,F交互=2.928 | |||||
P值 | P组间<0.010,P时间<0.010,P交互<0.010 |
组别 | 例数 | 化疗前1 d | 化疗第3天 | 化疗第7天 | 化疗第14天 | 化疗第21天 |
---|---|---|---|---|---|---|
对照组 | 47 | 209.55±50.05 | 177.55±37.99 | 153.02±31.66 | 135.87±36.74 | 189.30±42.12 |
揿针组 | 48 | 211.42±60.17 | 184.27±47.03 | 172.48±35.39a | 155.21±37.77a | 204.46±45.77 |
择时组 | 47 | 206.83±50.68 | 189.81±53.73 | 175.60±53.09a | 160.17±36.58a | 201.34±37.06 |
F值 | F组间=4.173,F时间=47.780,F交互=0.949 | |||||
P值 | P组间<0.050,P时间<0.010,P交互=0.468 |
Table 4 Comparison of platelet counts before and after chemotherapy among the three groups
组别 | 例数 | 化疗前1 d | 化疗第3天 | 化疗第7天 | 化疗第14天 | 化疗第21天 |
---|---|---|---|---|---|---|
对照组 | 47 | 209.55±50.05 | 177.55±37.99 | 153.02±31.66 | 135.87±36.74 | 189.30±42.12 |
揿针组 | 48 | 211.42±60.17 | 184.27±47.03 | 172.48±35.39a | 155.21±37.77a | 204.46±45.77 |
择时组 | 47 | 206.83±50.68 | 189.81±53.73 | 175.60±53.09a | 160.17±36.58a | 201.34±37.06 |
F值 | F组间=4.173,F时间=47.780,F交互=0.949 | |||||
P值 | P组间<0.050,P时间<0.010,P交互=0.468 |
组别 | 例数 | 化疗前1 d | 化疗第3天 | 化疗第7天 | 化疗第14天 | 化疗第21天 |
---|---|---|---|---|---|---|
对照组 | 47 | 4.44±0.33 | 4.50±0.38 | 4.39±0.31 | 4.44±0.39 | 4.27±0.28 |
揿针组 | 48 | 4.46±0.38 | 4.36±0.31 | 4.42±0.36 | 4.41±0.44 | 4.38±0.46 |
择时组 | 47 | 4.34±0.30 | 4.47±0.36 | 4.36±0.38 | 4.33±0.36 | 4.34±0.35 |
F值 | F组间=0.658,F时间=2.097,F交互=1.357 | |||||
P值 | P组间=0.519,P时间=0.080,P交互=0.213 |
Table 5 Comparison of RBC counts before and after chemotherapy among the three groups
组别 | 例数 | 化疗前1 d | 化疗第3天 | 化疗第7天 | 化疗第14天 | 化疗第21天 |
---|---|---|---|---|---|---|
对照组 | 47 | 4.44±0.33 | 4.50±0.38 | 4.39±0.31 | 4.44±0.39 | 4.27±0.28 |
揿针组 | 48 | 4.46±0.38 | 4.36±0.31 | 4.42±0.36 | 4.41±0.44 | 4.38±0.46 |
择时组 | 47 | 4.34±0.30 | 4.47±0.36 | 4.36±0.38 | 4.33±0.36 | 4.34±0.35 |
F值 | F组间=0.658,F时间=2.097,F交互=1.357 | |||||
P值 | P组间=0.519,P时间=0.080,P交互=0.213 |
组别 | 例数 | 化疗前1 d | 化疗第7天 | 化疗第14天 | 化疗第21天 |
---|---|---|---|---|---|
对照组 | 47 | 82.68±11.17 | 71.28±8.77 | 68.11±8.51 | 78.64±8.21 |
揿针组 | 48 | 80.40±13.27 | 75.40±8.63a | 71.85±7.35a | 81.75±8.90 |
择时组 | 47 | 81.02±9.70 | 77.87±9.78a | 75.06±7.57 ab | 81.85±9.65 |
F值 | F组间=4.300,F时间=47.267,F交互=3.227 | ||||
P值 | P组间=0.015,P时间<0.010,P交互<0.010 |
Table 6 Comparison of comfort scores before chemotherapy and on the 7th,14th,and 21st days of chemotherapy among the three groups
组别 | 例数 | 化疗前1 d | 化疗第7天 | 化疗第14天 | 化疗第21天 |
---|---|---|---|---|---|
对照组 | 47 | 82.68±11.17 | 71.28±8.77 | 68.11±8.51 | 78.64±8.21 |
揿针组 | 48 | 80.40±13.27 | 75.40±8.63a | 71.85±7.35a | 81.75±8.90 |
择时组 | 47 | 81.02±9.70 | 77.87±9.78a | 75.06±7.57 ab | 81.85±9.65 |
F值 | F组间=4.300,F时间=47.267,F交互=3.227 | ||||
P值 | P组间=0.015,P时间<0.010,P交互<0.010 |
组别 | 例数 | 地榆升白片 | 生血小板胶囊 | G-CSF | TPO |
---|---|---|---|---|---|
对照组 | 47 | 13 | 3 | 5 | 1 |
揿针组 | 48 | 10 | 2 | 3 | 1 |
择时组 | 47 | 8 | 2 | 2 | 0 |
Table 7 Comparison of the use of haematopoietic cell drugs after chemotherapy among the three groups
组别 | 例数 | 地榆升白片 | 生血小板胶囊 | G-CSF | TPO |
---|---|---|---|---|---|
对照组 | 47 | 13 | 3 | 5 | 1 |
揿针组 | 48 | 10 | 2 | 3 | 1 |
择时组 | 47 | 8 | 2 | 2 | 0 |
[1] |
庄凌云,毕倩宇,季旭明. 益气补血法治疗癌症化疗后骨髓抑制疗效的Meta分析[J]. 时珍国医国药,2020,31(8):2033-2037. DOI:10.3969/j.issn.1008-0805.2020.08.087.
|
[2] |
李先尧,黄裕,黄钊云,等. 基于子午流注理论应用三黄散护理湿热蕴结型痛风性关节炎疼痛患者效果观察[J]. 西部中医药,2022,35(9):142-145. DOI:10.12174/j.issn.2096-9600.2022.09.30.
|
[3] |
李苏茜,朱跃兰,张宏,等. 子午流注择时中药蜡疗改善膝骨关节炎患者焦虑抑郁的效果评价[J]. 北京中医药,2020,39(2):148-151. DOI:10.16025/j.1674-1307.2020.02.013.
|
[4] |
刘世儒,王鑫,邵向阳. 中医药防治放化疗所致骨髓抑制的研究进展[J]. 世界中西医结合杂志,2020,15(6):1169-1171. DOI:10.13935/j.cnki.sjzx.200646.
|
[5] |
曾妙,甘家丽,黄培锋,等. 中医药防治化疗后骨髓抑制疗效及药理机制研究进展[J]. 辽宁中医杂志,2020,47(10):213-216. DOI:10.13192/j.issn.1000-1719.2020.10.063.
|
[6] |
陈炎,陈亚蓓,陶荣芳. 《CSCO原发性肺癌诊疗指南2016》非小细胞肺癌治疗内容介绍[J]. 中国实用内科杂志,2017(S1):35-37.
|
[7] |
|
[8] |
孙燕,石远凯. 临床肿瘤内科手册[M]. 5版. 北京:人民卫生出版社,2007:316-323.
|
[9] |
黄岩,张力. 2020 CSCO非小细胞肺癌诊疗指南更新要点解读[J]. 临床内科杂志,2020,37(8):603-605. DOI:10.3969/j.issn.1001-9057.2020.08.023.
|
[10] |
凡国华,宋亚男,孙静云,等. 揿针耳穴联合腧穴治疗肺癌化疗患者睡眠障碍的疗效观察[J]. 护士进修杂志,2020,35(19):1803-1807. DOI:10.16821/j.cnki.hsjx.2020.19.017.
|
[11] |
王曙红. 临床护理评价量表及应用[M]. 长沙:湖南科学技术出版社,2011:146-149.
|
[12] |
侯黎莉,顾芬,周彩存. 经皮穴位电刺激预防肺癌患者化疗后骨髓抑制的效果观察[J]. 中华护理杂志,2016,51(1):57-61. DOI:10376/j.issn.0254-1796.2016.01.012.
|
[13] |
朱丽霞,高凤莉,梁晓坤,等. 胸外科术后72小时内患者舒适状况及影响因素研究[J]. 中华护理杂志,2007,42(3):225-228. DOI:10.3969/j.issn.1002-6975.2002.12.031.
|
[14] |
刘璐,李仁廷,崔旭旭. 李仁廷教授治疗化疗相关性骨髓抑制临床经验[J]. 陕西中医,2020,41(7):954-956. DOI:10.3969/j.issn.1000-7369.2020.07.035.
|
[15] |
肖彩芝,王维,夏冬琴. 艾灸联合中药穴位贴敷防治恶性肿瘤化疗后骨髓抑制的临床观察[J]. 中医肿瘤学杂志,2019,1(3):30-33. DOI:10.3969/j.issn.1006-4737.2017.02.021.
|
[16] |
赵方超,叶程远,王伟健,等. 经皮穴位电刺激预防非小细胞肺癌化疗相关性骨髓抑制临床观察[J]. 中国针灸,2020,40(6):596-600. DOI:10.13703/j.0255-2930.20190626-k0002.
|
[17] |
黄睿,李童,李美霞,等. 针刺治疗化疗后骨髓抑制的系统评价与Meta分析[J]. 中国针灸,2021,41(5):557-562. DOI:10.13703/j.0255-2930.20200618-k0005.
|
[18] |
宫园,杨丽华,侯庆梅. 隔药饼灸预防紫杉醇联合卡铂化疗患者骨髓抑制的效果观察[J]. 护理学杂志,2021,36(18):18-21. DOI:10.3870/j.issn.1001-4152.2021.18.018.
|
[19] |
谭丽,王宁. 基于数据挖掘技术分析艾灸治疗放化疗后骨髓抑制的选穴规律[J]. 时珍国医国药,2019,30(10):2534-2537. DOI:10.3969/j.issn.1008-0805.2019.10.076.
|
[20] |
吕红,姚冰,曾科学. 中药配合针刺三阴交对直肠癌患者术后化疗所致白细胞减少症的影响[J]. 辽宁中医杂志,2022,49(3):189-193. DOI:10.13192/j.issn.1000-1719.2022.03.053.
|
[21] |
张圣宏,孙民权,许玲,等.基于数据挖掘分析国内放化疗导致的骨髓抑制的用穴特点[J].中华中医药学刊,2016,34(8):1809-1812. DOI:10.13193/j.issn.1673-7717.2016.08.004.
|
[22] |
石健菲,焦丹丽,胡丹,等. 针灸治疗肿瘤化疗后骨髓抑制的最新研究进展[J]. 世界中医药,2022,17(22):3270-3274. DOI:10.3969/j.issn.1673-7202.2022.22.025.
|
[23] |
于冬冬,路玫,滕迎春,等. 针灸对CTX荷瘤小鼠骨髓细胞中Notch信号通路的影响[J]. 时珍国医国药,2020,31(10):2556-2558. DOI:10.3969/j.issn.1008-0805.2020.10.079.
|
[24] |
刘海伟,路玫. 针灸对CTX化疗小鼠骨髓造血微环境中骨髓基质细胞周期的影响[J]. 针灸临床杂志,2020,36(4):76-80. DOI:10.3969/j.issn.1005-0779.2020.04.019.
|
[25] |
高雅婷,吴迪,李泽庚,等.中西医结合干预疗法对肺癌患者生活质量影响的Meta分析[J].世界科学技术-中医药现代化,2020,22(7):2246-2255. DOI:10.11842/wst.20190626010.
|
[26] |
程梦慧,卢咏梅,黎玉婵,等. 子午流注纳支法中药沐足并按摩对乳腺癌患者首次化疗后骨髓抑制的临床护理研究[J]. 护士进修杂志,2018,33(10):876-879.
|
[27] |
李红霞,高丽娜,宗倩倩,等.子午流注针刺联合直流电药物离子导入治疗糖尿病合并顽固性失眠的临床观察[J].世界最新医学信息文摘,2019,19(5):171-172. DOI:10.19613/j.cnki.1671-3141.2019.05.123.
|
[1] | LI Qianqian, CHEN Xunrui, ZHANG Wenying, YUAN Haihua, ZHANG Yanjie, JIANG Bin, LIU Feng. Demand and Influencing Factors for Community Health Services during Chemotherapy of Patients with Advanced Cancer [J]. Chinese General Practice, 2023, 26(33): 4173-4180. |
[2] | ZHANG Ming, XU Jing, SUN Zhenhua, ZHAO Wenhao, MA Yingqian, ZHANG Jianqiao, SHEN Haiping. Improvement of Nutritional Status of Elderly Patients with Severe Obstruction Esophageal Carcinoma by Image-guided Photodynamic Therapy [J]. Chinese General Practice, 2023, 26(30): 3780-3784. |
[3] | YAN Ke, WEI Wanyi, LI Shuguang, YAO Weinan, DONG Jing, WANG Xiaobin, ZHANG Xueyuan, YANG Jie, SHEN Wenbin, ZHU Shuchai. Effect of Consolidation Chemotherapy on Prognosis of StageⅡ-Ⅲ Esophageal Squamous Cell Carcinoma Patients Treated with Definitive Concurrent Chemotherapy and Radio-therapy [J]. Chinese General Practice, 2023, 26(30): 3772-3779. |
[4] | PEI Bei, CHENG Lin, XU Lingyun. Effects of Different Neoadjuvant Chemotherapy Regimens on Immune Indicators and Tumor Microenvironment in HER-2-positive Breast Cancer Patients [J]. Chinese General Practice, 2023, 26(27): 3435-3440. |
[5] | WANG Jun, WU Jiafei, WANG Yijing, ZHENG Boyue, WANG Yu, JIANG Chuanyan, LI Hui. Efficacy and Prognostic Effect of Daratumumab-based Chemotherapy Regimen in Multiple Myeloma: a Real-world Study [J]. Chinese General Practice, 2023, 26(18): 2256-2262. |
[6] | Ziqiang HONG, Dacheng JIN, Xiangdou BAI, Baiqiang CUI, Yunjiu GOU. Recent Advances in the Diagnosis and Management of Multiple Primary Lung Cancer [J]. Chinese General Practice, 2022, 25(27): 3435-3442. |
[7] | Aimei WANG, Xinqiong ZHANG, Tingting WANG, Liang ZHANG, Xuewei LIU, Jingwen WANG, Ying MA, Wenxiu ZHOU, Dawei YIN. Establishment of the Norms of Exercise Self-efficacy Scale for Lung Cancer Patients in Anhui Province [J]. Chinese General Practice, 2022, 25(13): 1603-1611. |
[8] |
CHEN Xiaofeng, WANG Meng, LI Zhongyu, LI Jiajia.
Clinical Study of Venetoclax with Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia [J]. Chinese General Practice, 2022, 25(08): 957-962. |
[9] | XUE Mengting,YANG Min,PAN Yalan,TAN Jiani,HUANG Anle,BU Zihan,WANG Qing,XU Guihua. Traditional Chinese Medicine for the Prevention and Treatment of Bone Marrow Suppression after Chemotherapy Based on AMSTAR 2 and GRADE:an Overview of Systematic Reviews and Meta-Analyses [J]. Chinese General Practice, 2021, 24(6): 718-726. |
[10] | PENG Lei,MENG Chunyang,LI Jinze,LI Yunxiang,LI Jinming,ZHAO Pan,WEI Tangqiang,WU Ji. Gemcitabine Has a Lower Recurrence Rate and Less Side Effects than Mitomycin for Non-muscular Invasive Bladder Cancer after TURBT:a Meta-analysis of Randomized Controlled Trials [J]. Chinese General Practice, 2021, 24(23): 2978-2984. |
[11] | WANG Jiuxiang,CHENG Qingfeng,ZHU Shenyin,CHEN Huanhuan,DU Zhipeng,TANG Ziwei. Pilot Clinical Study of Methylene Blue-mediated Photodynamic Antibacterial Chemotherapy to Improve Diabetic Lower Extremity Ulcer Infection [J]. Chinese General Practice, 2021, 24(15): 1903-1908. |
[12] | LI Ying,WANG Zukang,WEI Youliang,GONG Zhihua. Recurrence and Associated Factors in Cured Patients with Newly Diagnosed Smear-positive Pulmonary Tuberculosis:a Follow-up Study [J]. Chinese General Practice, 2021, 24(14): 1785-1789. |
[13] | SONG Yannan,YIN Wenqiang,LIU Min,LI Qiusha,LIU Qian,HUANG Yanan,XU Xiaofeng,HUANG Dongmei. Hospitalization Cost and Its Structural Variation for Four Kinds of Malignant Tumors in China from 2013 to 2017 [J]. Chinese General Practice, 2020, 23(6): 649-655. |
[14] | AIKEREMU?Yusufu,ABUDUSHALAMU?Yimiti,ZAIYINUER?Abuduwaili,ROUSIDAN?Tuerdi,PAERHATI?Shayimu,WANG Haijiang. Evaluation of Safety,Efficacy and Hospitalization Cost of Three Neoadjuvant Chemotherapy Regimens for Advanced Gastric Cancer [J]. Chinese General Practice, 2020, 23(26): 3286-3290. |
[15] | ZHANG Xiaoqin,CHEN Xuanyi,WU Shengchang. Value of Circulating Tumor Cells in Chemotherapy Efficacy Monitoring and Prognosis Prediction of Advanced Non-small Cell Lung Cancer [J]. Chinese General Practice, 2020, 23(2): 183-188. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||